[go: up one dir, main page]

UA94034C2 - Аналоги рапамицина и их применение в лечении неврологических, пролиферативных и воспалительных расстройств - Google Patents

Аналоги рапамицина и их применение в лечении неврологических, пролиферативных и воспалительных расстройств

Info

Publication number
UA94034C2
UA94034C2 UAA200706849A UAA200706849A UA94034C2 UA 94034 C2 UA94034 C2 UA 94034C2 UA A200706849 A UAA200706849 A UA A200706849A UA A200706849 A UAA200706849 A UA A200706849A UA 94034 C2 UA94034 C2 UA 94034C2
Authority
UA
Ukraine
Prior art keywords
proliferative
neurologial
rapamcyin
analogues
treatment
Prior art date
Application number
UAA200706849A
Other languages
English (en)
Ukrainian (uk)
Inventor
Эдмунд Идрис Грациани
Кевин Понг
Джераульд Скотницки
Original Assignee
Уайет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уайет filed Critical Уайет
Publication of UA94034C2 publication Critical patent/UA94034C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение обеспечивает соединения следующей структуры,в котором R, R, R, R, R, Rи Rпринимают значения, представленные в формуле изобретения.Указанные соединения пригодны для лечения неврологических расстройств или осложнений, вызванных инсультом или поражением головы; доброкачественной или злокачественной неопластической болезни, карцином и аденокарцином; пролиферативных расстройств и воспалительных расстройств. Поэтому эти соединения пригодны в качестве нейропротективных и нейрорегенеративных, антипролиферативных и противовоспалительных агентов.
UAA200706849A 2004-12-20 2005-12-15 Аналоги рапамицина и их применение в лечении неврологических, пролиферативных и воспалительных расстройств UA94034C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63766604P 2004-12-20 2004-12-20

Publications (1)

Publication Number Publication Date
UA94034C2 true UA94034C2 (ru) 2011-04-11

Family

ID=36087657

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200706849A UA94034C2 (ru) 2004-12-20 2005-12-15 Аналоги рапамицина и их применение в лечении неврологических, пролиферативных и воспалительных расстройств

Country Status (26)

Country Link
US (5) US7276498B2 (ru)
EP (1) EP1828202B1 (ru)
JP (1) JP5094406B2 (ru)
KR (1) KR20070090913A (ru)
CN (1) CN101084227B (ru)
AR (1) AR052269A1 (ru)
AT (1) ATE549342T1 (ru)
AU (1) AU2005319454B2 (ru)
BR (1) BRPI0519495A2 (ru)
CA (1) CA2590155A1 (ru)
CR (1) CR9148A (ru)
DK (1) DK1828202T3 (ru)
ES (1) ES2380779T3 (ru)
GT (1) GT200500368A (ru)
HN (1) HN2005035605A (ru)
IL (1) IL183664A (ru)
MX (1) MX2007007408A (ru)
NI (1) NI200700157A (ru)
NO (1) NO20072664L (ru)
NZ (1) NZ574663A (ru)
PE (1) PE20060765A1 (ru)
RU (1) RU2394036C2 (ru)
SG (1) SG158143A1 (ru)
TW (1) TW200628152A (ru)
UA (1) UA94034C2 (ru)
WO (1) WO2006068932A2 (ru)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101131794B1 (ko) 2002-07-30 2012-03-30 와이어쓰 엘엘씨 Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법
US7247650B2 (en) * 2004-03-02 2007-07-24 Wyeth Macrolides and methods for producing same
JP2008501342A (ja) * 2004-06-03 2008-01-24 ワイス 複合ポリケチドを生成するための生合成遺伝子クラスター
BRPI0519593A2 (pt) * 2004-12-20 2009-02-25 Wyeth Corp composto, mÉtodos de tratar distérbios neurodegenerativos e complicaÇÕes devido a derrame ou trauma na cabeÇa, e de preparar um composto, e, uso de um composto
HN2005035605A (es) * 2004-12-20 2010-08-05 Wyeth Corp Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
JP2009518412A (ja) * 2005-12-07 2009-05-07 ワイス ラパマイシン４２−エステルボロネートからラパマイシン４２−エステルを調製するためのスケーラブルな方法
PE20071000A1 (es) * 2005-12-07 2007-10-10 Wyeth Corp Metodos para la preparacion de rapamicina cristalina y para la medicion de la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido
PE20071041A1 (es) * 2005-12-07 2007-12-07 Wyeth Corp Forma cristalina purificada de cci-779 y proceso para la preparacion del mismo
CA2643350A1 (en) 2006-03-07 2007-09-13 Wyeth Meridamycin analogues for the treatment of neurodegenerative disorders
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
TW200824713A (en) * 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
JP2010521419A (ja) * 2007-01-29 2010-06-24 ワイス エルエルシー イムノフィリンおよびカルシウムチャネル活性を調整するためのイムノフィリンリガンドおよび方法
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
US8653045B2 (en) 2008-02-05 2014-02-18 The Johns Hopkins University Induction of thyroid iodide-handling gene expression in human cancers
US20090209527A1 (en) * 2008-02-19 2009-08-20 Wyeth Methods for Using Rapamycin Analogues in the Treatment of Neurological Disorders
ES2645692T3 (es) 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
WO2010118419A2 (en) 2009-04-10 2010-10-14 Haiyan Qi Novel anti-aging agents and methods to identify them
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2015103447A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US20170079962A1 (en) 2009-11-11 2017-03-23 Rapamycin Holdings, Llc Oral Rapamycin Preparation and Use for Stomatitus
CA2794196A1 (en) 2010-03-23 2011-09-29 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
ES2372077B2 (es) * 2010-06-24 2012-05-18 Universidad De Sevilla Uso de la rapamicina para el tratamiento de los déficits cognitivos asociados al s�?ndrome de down.
EP2446886A1 (en) * 2010-10-29 2012-05-02 Fondazione Telethon Autophagy regulators and the uses thereof in the treatment of collagen VI defective Muscular Dystrophies
CN103534355A (zh) 2011-03-04 2014-01-22 英特瑞克斯顿股份有限公司 条件性表达蛋白质的载体
EP2589383A1 (en) 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP subtype-specific rapamycin analogue for use in treatment of diseases
CA2926747A1 (en) 2012-10-12 2014-04-17 Arlan RICHARDSON Use of mtor inhibitors to treat vascular cognitive impairment
ITMI20122065A1 (it) * 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
DK2968281T3 (da) 2013-03-13 2020-11-02 Univ Texas Mtor-hæmmere til forebyggelse af vækst af tarmpolyp
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
GB2538747B (en) * 2015-05-27 2022-04-13 Airbus Operations Ltd A measuring apparatus for measuring properties of a surface
EP3310786B1 (en) 2015-06-16 2021-03-03 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
UY37343A (es) 2016-07-25 2018-02-28 Intrexon Corp Control del fenotipo en plantas
EP3538660A1 (en) 2016-11-09 2019-09-18 Intrexon Corporation Frataxin expression constructs
ES2871499T3 (es) 2017-05-15 2021-10-29 Bard Inc C R Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia
WO2020076738A2 (en) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
WO2020101675A1 (en) 2018-11-14 2020-05-22 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
CN113766916B (zh) * 2019-01-22 2024-04-05 艾奥维安制药公司 Mtorc调节剂及其用途
WO2020209828A1 (en) 2019-04-08 2020-10-15 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface
EP4185590A2 (en) * 2020-07-21 2023-05-31 Aeovian Pharmaceuticals, Inc. Mtorc1 modulators and uses thereof
CN115887452A (zh) * 2022-01-27 2023-04-04 中以海德人工智能药物研发股份有限公司 雷帕霉素在治疗或预防乙型肝炎中的应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
DE1545824A1 (de) 1965-06-21 1969-12-11 Bayer Ag Verfahren zur Herstellung von 2-Sulfonamido- bzw. 2-Sulfonhydrazido-Benzoxazinonen
CA930734A (en) * 1969-08-11 1973-07-24 Bickel Hans Antibiotically active rifamycin compounds and processes for their manufacture
US3686238A (en) * 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3900465A (en) * 1973-04-05 1975-08-19 Lepetit Spa 3-formylrifamycin azines
US3905981A (en) * 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US4127720A (en) * 1977-09-21 1978-11-28 Bristol-Myers Company Pyrimido[2,1-a]isoquinoline derivatives having antiallergy activity
JPH0262875A (ja) 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd 新規イソインドリン誘導体
WO1991019495A1 (en) 1990-06-11 1991-12-26 Fujisawa Pharmaceutical Co., Ltd. Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
DE4021404A1 (de) 1990-07-05 1992-01-09 Sandoz Ag Heteroatome enthaltende trycyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
GB2249027A (en) 1990-10-23 1992-04-29 Fujisawa Pharmaceutical Co Use of macrolide compounds for hepatic failure
WO1992013862A1 (en) 1991-02-05 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Lactone compounds
US5604294A (en) * 1991-09-05 1997-02-18 Luly; Jay R. Macrocyclic immunomodulators
JP3644957B2 (ja) 1991-09-05 2005-05-11 アボット・ラボラトリーズ 大環式イムノモジュレーター
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
DE69435044T2 (de) 1993-04-23 2008-09-18 Wyeth Rapamycin - Konjugate und Antikörper
US7279561B1 (en) * 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
AU712193B2 (en) * 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US5717092A (en) * 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US6187784B1 (en) * 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Pipecolic acid derivative hair growth compositions and uses
AU761083B2 (en) 1998-06-03 2003-05-29 Gpi Nil Holdings, Inc. Pipecolic acid derivative hair growth compositions and uses
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
AU5487499A (en) 1998-08-17 2000-03-06 American Home Products Corporation Photocyclized rapamycins
WO2000034239A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CA2384151A1 (en) 1999-09-09 2001-03-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6569867B2 (en) * 1999-10-01 2003-05-27 Kosan Biosciences, Inc. Polyketide derivatives
AU2748701A (en) 1999-10-29 2001-06-06 Kosan Biosciences, Inc. Rapamycin analogs
AU6143201A (en) 2000-05-17 2001-11-26 Kosan Biosciences Inc Novel polyketide derivatives
CN1545512A (zh) 2001-08-22 2004-11-10 惠氏公司 雷帕霉素二醛化合物
WO2003018573A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin 29-enols
US7300942B2 (en) 2002-07-16 2007-11-27 Biotica Technology Limited Production of polyketides and other natural products
DE102004049700B4 (de) 2004-10-12 2007-10-18 Aircabin Gmbh Kraftunterstützungsvorrichtung mit lastabhängiger Kraftunterstützung
HN2005035605A (es) 2004-12-20 2010-08-05 Wyeth Corp Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
BRPI0519593A2 (pt) * 2004-12-20 2009-02-25 Wyeth Corp composto, mÉtodos de tratar distérbios neurodegenerativos e complicaÇÕes devido a derrame ou trauma na cabeÇa, e de preparar um composto, e, uso de um composto
CA2643350A1 (en) 2006-03-07 2007-09-13 Wyeth Meridamycin analogues for the treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
RU2394036C2 (ru) 2010-07-10
CN101084227A (zh) 2007-12-05
SG158143A1 (en) 2010-01-29
US7795252B2 (en) 2010-09-14
WO2006068932A2 (en) 2006-06-29
US20080004264A1 (en) 2008-01-03
GT200500368A (es) 2006-07-13
IL183664A (en) 2012-06-28
BRPI0519495A2 (pt) 2009-02-03
US7470682B2 (en) 2008-12-30
TW200628152A (en) 2006-08-16
US20060135549A1 (en) 2006-06-22
AU2005319454B2 (en) 2012-08-09
CN101084227B (zh) 2011-11-16
HN2005035605A (es) 2010-08-05
HK1108442A1 (en) 2008-05-09
AR052269A1 (es) 2007-03-07
RU2007119584A (ru) 2009-01-27
PE20060765A1 (es) 2006-10-02
KR20070090913A (ko) 2007-09-06
US20070142423A1 (en) 2007-06-21
US7560457B2 (en) 2009-07-14
CR9148A (es) 2007-11-23
JP5094406B2 (ja) 2012-12-12
DK1828202T3 (da) 2012-05-07
EP1828202B1 (en) 2012-03-14
JP2008524240A (ja) 2008-07-10
US20090203682A1 (en) 2009-08-13
AU2005319454A1 (en) 2006-06-29
ATE549342T1 (de) 2012-03-15
US7276498B2 (en) 2007-10-02
US20090239855A1 (en) 2009-09-24
ES2380779T3 (es) 2012-05-18
MX2007007408A (es) 2007-07-12
EP1828202A2 (en) 2007-09-05
NZ574663A (en) 2010-05-28
WO2006068932A3 (en) 2006-10-19
NO20072664L (no) 2007-06-25
IL183664A0 (en) 2007-09-20
CA2590155A1 (en) 2006-06-29
NI200700157A (es) 2008-04-21

Similar Documents

Publication Publication Date Title
UA94034C2 (ru) Аналоги рапамицина и их применение в лечении неврологических, пролиферативных и воспалительных расстройств
MX2007007409A (es) Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos.
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
WO2005013996A3 (en) 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
WO2002080890A3 (en) A jasmonate pharmaceutical composition for treatment of cancer
TW200616627A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
ES2391382T8 (es) Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
NZ531404A (en) Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
IL184866A0 (en) Treatment of metastasized tumors
AU5173501A (en) Polyamine analogues as cytotoxic agents
WO2004074454A3 (en) Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
EP1507778A4 (en) ANTI-TUMOR POLYCYCLIC CARBOXAMIDES
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
DE602004022578D1 (de) Antitumorale terpen-verbindungen
WO2003014128A3 (de) Tumorhemmende cerverbindungen
IL159469A0 (en) Xenogenic oligo-or/and polyribonucleotides as agents for the treatment of malignant tumours